Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine. Show more

Location: 34790 Ardentech Ct, California, 94555-3657, US | Website: www.zosanopharma.com | Industry: | Sector:


Market Cap

901.4M

52 Wk Range

$N/A - $N/A

Previous Close

$0.00

Open

$0.00

Volume

5,685

Day Range

$0.00 - $0.00

Enterprise Value

0.00

Cash

159.3M

Avg Qtr Burn

N/A

Insider Ownership

0.00%

Institutional Own.

0.00%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date